Brief: Lineage Cell Therapeutics - Announces Exclusive Option Agreement With Amasa Therapeutics For Supply And Use Of Clinical-Grade Hystem
17/06/2021 13:06
June 17 (Reuters) - Lineage Cell Therapeutics Inc LCTX.A :
* LINEAGE CELL THERAPEUTICS - ANNOUNCES EXCLUSIVE OPTION
AGREEMENT
WITH AMASA THERAPEUTICS FOR SUPPLY AND USE OF CLINICAL-GRADE
HYSTEM
Source text for Eikon: ID:nBwcdWB2Ta
Further company coverage: LCTX.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lineage Cell Therapeutics
See all newsLineage Cell Therapeutics Q2 revenue falls but posts profit
Brief: Lineage Cell Therapeutics Q2 Income From Operations USD -8.923 Million
Lineage Cell Therapeutics Q1 net loss widens as expenses rise
Lineage Cell Q4 revenue rises on Genentech collaboration
Brief: Lineage Cell Therapeutics FY Income From Operations USD -36.619 Million